Close

Kezar Life Sciences (KZR) Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

Go back to Kezar Life Sciences (KZR) Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
(NASDAQ: KZR) Delayed: 8.61 -0.01 (0.12%)
Previous Close $8.62    52 Week High
Open $8.68    52 Week Low
Day High $9.00    P/E N/A 
Day Low $8.53    EPS
Volume 918,241